Bartlett & CO. Wealth Management LLC Increases Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Bartlett & CO. Wealth Management LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 15.2% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 353,262 shares of the company's stock after acquiring an additional 46,672 shares during the period. Bartlett & CO. Wealth Management LLC owned about 0.08% of Zoetis worth $58,165,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Rakuten Securities Inc. lifted its stake in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after purchasing an additional 166 shares in the last quarter. Navigoe LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at approximately $30,000. Murphy & Mullick Capital Management Corp purchased a new position in Zoetis during the fourth quarter worth approximately $44,000. Sound Income Strategies LLC boosted its stake in Zoetis by 141.4% during the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after buying an additional 164 shares during the last quarter. Finally, Bfsg LLC increased its stake in shares of Zoetis by 614.6% in the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after acquiring an additional 252 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president now directly owns 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.18% of the stock is owned by company insiders.

Zoetis Price Performance

ZTS stock opened at $156.01 on Friday. The company has a market capitalization of $69.46 billion, a PE ratio of 28.01, a P/E/G ratio of 2.61 and a beta of 0.94. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. The business's fifty day moving average price is $160.25 and its 200 day moving average price is $162.87. Zoetis Inc. has a 12-month low of $139.70 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The business had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter last year, the firm posted $1.38 earnings per share. The business's revenue for the quarter was up 1.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.28%. Zoetis's payout ratio is 35.91%.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent research reports. Piper Sandler boosted their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Monday, May 12th. Wall Street Zen raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. UBS Group reduced their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $212.13.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.